El jueves y viernes 10 y 11 de mayo del 2018 realizamos en la Fundación Ramón Areces un Simposio Internacional, en el cual se trató el tema del mosaicismo somático en malformaciones vasculares.
A presentation on the latest technique to remove the thyroid gland; via the transoral route. This novel technique is a form natural orifice trans-endoscopic surgery (NOTES) and is truly scarless. Comparisons with the traditional open and other remote endoscopic techniques are explored.
A presentation on the latest technique to remove the thyroid gland; via the transoral route. This novel technique is a form natural orifice trans-endoscopic surgery (NOTES) and is truly scarless. Comparisons with the traditional open and other remote endoscopic techniques are explored.
Los días 20 y 21 de octubre de 2016, la Fundacion Ramón Areces organizó un simposio internacional para analizar las 'Enfermedades raras de la piel: de la clínica al gen y viceversa'. El doctor Fernando Larcher Laguzzi, del CIEMAT-Universidad Carlos III de Madrid-IIS Fundación Jiménez Díaz, ejerció de coordinador.
History of DICER1 mutation
DICER1 function
Mutated DICER1 – tumorigenic mechanism
Constellation of lesions associated with DICER1
DICER1 IHC
When to test?
Therapeutic options
Jordi Torren - Coordinador del proyecto ESVAC. Agencia Europea de Medicamento...Fundación Ramón Areces
El martes 5 de junio del 2018 organizamos una Jornada en la Fundación Ramón Areces, en la cual se habló sobre el consumo de antibióticos y transmisión de resistencia entre humanos y animales.
Dominique L. Monnet Director del programa ARHAI (Antimicrobial Resistance an...Fundación Ramón Areces
El martes 5 de junio del 2018 organizamos una Jornada en la Fundación Ramón Areces, en la cual se habló sobre el consumo de antibióticos y transmisión de resistencia entre humanos y animales.
More Related Content
Similar to Rudolf Happle - Dermatología, University of Freiburg Medical Center, Freiburg, Alemania.
Los días 20 y 21 de octubre de 2016, la Fundacion Ramón Areces organizó un simposio internacional para analizar las 'Enfermedades raras de la piel: de la clínica al gen y viceversa'. El doctor Fernando Larcher Laguzzi, del CIEMAT-Universidad Carlos III de Madrid-IIS Fundación Jiménez Díaz, ejerció de coordinador.
History of DICER1 mutation
DICER1 function
Mutated DICER1 – tumorigenic mechanism
Constellation of lesions associated with DICER1
DICER1 IHC
When to test?
Therapeutic options
Jordi Torren - Coordinador del proyecto ESVAC. Agencia Europea de Medicamento...Fundación Ramón Areces
El martes 5 de junio del 2018 organizamos una Jornada en la Fundación Ramón Areces, en la cual se habló sobre el consumo de antibióticos y transmisión de resistencia entre humanos y animales.
Dominique L. Monnet Director del programa ARHAI (Antimicrobial Resistance an...Fundación Ramón Areces
El martes 5 de junio del 2018 organizamos una Jornada en la Fundación Ramón Areces, en la cual se habló sobre el consumo de antibióticos y transmisión de resistencia entre humanos y animales.
El jueves 24 de mayo del 2018 organizamos una Conferencia con Antonio Cabrales en la Fundación Ramón Areces. Una conferencia en la cual el tema fue: Estilo negociador y confianza, ¿hay diferencias entre hombres y mujeres?
Teresa Puig - Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Espa...Fundación Ramón Areces
El lunes y martes 21 y 22 de mayo del 2018 realizamos un Simposio Internacional en la Fundación Ramón Areces, tratando el tema de la superconductividad y presión: una relación fructífera en el camino hacia la superconductividad a temperatura ambiente.
Elena Bascones - Instituto de Ciencia de Materiales de Madrid (ICMM-CSIC), Es...Fundación Ramón Areces
El lunes y martes 21 y 22 de mayo del 2018 realizamos un Simposio Internacional en la Fundación Ramón Areces, tratando el tema de la superconductividad y presión: una relación fructífera en el camino hacia la superconductividad a temperatura ambiente.
El jueves 17 de mayo del 2018 se organizó una Mesa Redonda en la Fundación Ramón Areces, en la cual se habló sobre las subidas de tipos en la era Trump y la nueva globalización.
El jueves 17 de mayo del 2018 se organizó una Mesa Redonda en la Fundación Ramón Areces, en la cual se habló sobre las subidas de tipos en la era Trump y la nueva globalización.
El miércoles 16 de mayo del 2018 celebramos una Jornada en la Fundación Ramón Areces, en la cual se habló sobre las nuevas fronteras de investigación sobre la distribución comercial y el comportamiento del consumidor.
El miércoles 16 de mayo del 2018 celebramos una Jornada en la Fundación Ramón Areces, en la cual se habló sobre las nuevas fronteras de investigación sobre la distribución comercial y el comportamiento del consumidor.
Juan Carlos López-Gutiérrez - Unidad de Anomalías Vasculares, Hospital Unive...Fundación Ramón Areces
El jueves y viernes 10 y 11 de mayo del 2018 realizamos en la Fundación Ramón Areces un Simposio Internacional, en el cual se trató el tema del mosaicismo somático en malformaciones vasculares.
Víctor Martínez-Glez. - Instituto de Genética Médica y Molecular (INGEMM). I...Fundación Ramón Areces
El jueves y viernes 10 y 11 de mayo del 2018 realizamos en la Fundación Ramón Areces un Simposio Internacional, en el cual se trató el tema del mosaicismo somático en malformaciones vasculares.
Rafael Doménech - Responsable de Análisis Macroeconómico, BBVA Research. Fundación Ramón Areces
El martes 8 de mayo de 2018 realizamos una conferencia en la Fundación Ramón Areces, en la cual se habló sobre el futuro de las pensiones: una visión global.
El martes 8 de mayo de 2018 realizamos una conferencia en la Fundación Ramón Areces, en la cual se habló sobre el futuro de las pensiones: una visión global.
El martes 8 de mayo de 2018 realizamos una conferencia en la Fundación Ramón Areces, en la cual se habló sobre el futuro de las pensiones: una visión global.
Nicholas Barr - Profesor de Economía Pública, London School of Economics. Fundación Ramón Areces
El martes 8 de mayo de 2018 realizamos una conferencia en la Fundación Ramón Areces, en la cual se habló sobre el futuro de las pensiones: una visión global.
El viernes 27 de abril del 2018 se celebró en la Fundación Ramón Areces una Jornada sobre física , en la cual se trataron diversos temas como: Los materiales mecanocalóricos, magnetísmo, biofísica, la energía oscura y instrumentación astronómica.
El viernes 20 de abril organizamos una Jornada sobre la ciencia en el corazón de Europa, en colaboración con Científicos Españoles en Bélgica (CEBE) y realizada en la Fundación Ramón Areces.
Marta Olivares - Investigadora Postdoctoral en Université catholique de Louva...Fundación Ramón Areces
El viernes 20 de abril organizamos una Jornada sobre la ciencia en el corazón de Europa, en colaboración con Científicos Españoles en Bélgica (CEBE) y realizada en la Fundación Ramón Areces.
El viernes 20 de abril organizamos una Jornada sobre la ciencia en el corazón de Europa, en colaboración con Científicos Españoles en Bélgica (CEBE) y realizada en la Fundación Ramón Areces.
Víctor R. de la Rosa - Investigador en Universiteit Gent (UGent) y fundador d...Fundación Ramón Areces
El viernes 20 de abril organizamos una Jornada sobre la ciencia en el corazón de Europa, en colaboración con Científicos Españoles en Bélgica (CEBE) y realizada en la Fundación Ramón Areces.
Cancer cell metabolism: special Reference to Lactate PathwayAADYARAJPANDEY1
Normal Cell Metabolism:
Cellular respiration describes the series of steps that cells use to break down sugar and other chemicals to get the energy we need to function.
Energy is stored in the bonds of glucose and when glucose is broken down, much of that energy is released.
Cell utilize energy in the form of ATP.
The first step of respiration is called glycolysis. In a series of steps, glycolysis breaks glucose into two smaller molecules - a chemical called pyruvate. A small amount of ATP is formed during this process.
Most healthy cells continue the breakdown in a second process, called the Kreb's cycle. The Kreb's cycle allows cells to “burn” the pyruvates made in glycolysis to get more ATP.
The last step in the breakdown of glucose is called oxidative phosphorylation (Ox-Phos).
It takes place in specialized cell structures called mitochondria. This process produces a large amount of ATP. Importantly, cells need oxygen to complete oxidative phosphorylation.
If a cell completes only glycolysis, only 2 molecules of ATP are made per glucose. However, if the cell completes the entire respiration process (glycolysis - Kreb's - oxidative phosphorylation), about 36 molecules of ATP are created, giving it much more energy to use.
IN CANCER CELL:
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
introduction to WARBERG PHENOMENA:
WARBURG EFFECT Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside.
Otto Heinrich Warburg (; 8 October 1883 – 1 August 1970) In 1931 was awarded the Nobel Prize in Physiology for his "discovery of the nature and mode of action of the respiratory enzyme.
WARNBURG EFFECT : cancer cells under aerobic (well-oxygenated) conditions to metabolize glucose to lactate (aerobic glycolysis) is known as the Warburg effect. Warburg made the observation that tumor slices consume glucose and secrete lactate at a higher rate than normal tissues.
Slide 1: Title Slide
Extrachromosomal Inheritance
Slide 2: Introduction to Extrachromosomal Inheritance
Definition: Extrachromosomal inheritance refers to the transmission of genetic material that is not found within the nucleus.
Key Components: Involves genes located in mitochondria, chloroplasts, and plasmids.
Slide 3: Mitochondrial Inheritance
Mitochondria: Organelles responsible for energy production.
Mitochondrial DNA (mtDNA): Circular DNA molecule found in mitochondria.
Inheritance Pattern: Maternally inherited, meaning it is passed from mothers to all their offspring.
Diseases: Examples include Leber’s hereditary optic neuropathy (LHON) and mitochondrial myopathy.
Slide 4: Chloroplast Inheritance
Chloroplasts: Organelles responsible for photosynthesis in plants.
Chloroplast DNA (cpDNA): Circular DNA molecule found in chloroplasts.
Inheritance Pattern: Often maternally inherited in most plants, but can vary in some species.
Examples: Variegation in plants, where leaf color patterns are determined by chloroplast DNA.
Slide 5: Plasmid Inheritance
Plasmids: Small, circular DNA molecules found in bacteria and some eukaryotes.
Features: Can carry antibiotic resistance genes and can be transferred between cells through processes like conjugation.
Significance: Important in biotechnology for gene cloning and genetic engineering.
Slide 6: Mechanisms of Extrachromosomal Inheritance
Non-Mendelian Patterns: Do not follow Mendel’s laws of inheritance.
Cytoplasmic Segregation: During cell division, organelles like mitochondria and chloroplasts are randomly distributed to daughter cells.
Heteroplasmy: Presence of more than one type of organellar genome within a cell, leading to variation in expression.
Slide 7: Examples of Extrachromosomal Inheritance
Four O’clock Plant (Mirabilis jalapa): Shows variegated leaves due to different cpDNA in leaf cells.
Petite Mutants in Yeast: Result from mutations in mitochondrial DNA affecting respiration.
Slide 8: Importance of Extrachromosomal Inheritance
Evolution: Provides insight into the evolution of eukaryotic cells.
Medicine: Understanding mitochondrial inheritance helps in diagnosing and treating mitochondrial diseases.
Agriculture: Chloroplast inheritance can be used in plant breeding and genetic modification.
Slide 9: Recent Research and Advances
Gene Editing: Techniques like CRISPR-Cas9 are being used to edit mitochondrial and chloroplast DNA.
Therapies: Development of mitochondrial replacement therapy (MRT) for preventing mitochondrial diseases.
Slide 10: Conclusion
Summary: Extrachromosomal inheritance involves the transmission of genetic material outside the nucleus and plays a crucial role in genetics, medicine, and biotechnology.
Future Directions: Continued research and technological advancements hold promise for new treatments and applications.
Slide 11: Questions and Discussion
Invite Audience: Open the floor for any questions or further discussion on the topic.
Richard's aventures in two entangled wonderlandsRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
The increased availability of biomedical data, particularly in the public domain, offers the opportunity to better understand human health and to develop effective therapeutics for a wide range of unmet medical needs. However, data scientists remain stymied by the fact that data remain hard to find and to productively reuse because data and their metadata i) are wholly inaccessible, ii) are in non-standard or incompatible representations, iii) do not conform to community standards, and iv) have unclear or highly restricted terms and conditions that preclude legitimate reuse. These limitations require a rethink on data can be made machine and AI-ready - the key motivation behind the FAIR Guiding Principles. Concurrently, while recent efforts have explored the use of deep learning to fuse disparate data into predictive models for a wide range of biomedical applications, these models often fail even when the correct answer is already known, and fail to explain individual predictions in terms that data scientists can appreciate. These limitations suggest that new methods to produce practical artificial intelligence are still needed.
In this talk, I will discuss our work in (1) building an integrative knowledge infrastructure to prepare FAIR and "AI-ready" data and services along with (2) neurosymbolic AI methods to improve the quality of predictions and to generate plausible explanations. Attention is given to standards, platforms, and methods to wrangle knowledge into simple, but effective semantic and latent representations, and to make these available into standards-compliant and discoverable interfaces that can be used in model building, validation, and explanation. Our work, and those of others in the field, creates a baseline for building trustworthy and easy to deploy AI models in biomedicine.
Bio
Dr. Michel Dumontier is the Distinguished Professor of Data Science at Maastricht University, founder and executive director of the Institute of Data Science, and co-founder of the FAIR (Findable, Accessible, Interoperable and Reusable) data principles. His research explores socio-technological approaches for responsible discovery science, which includes collaborative multi-modal knowledge graphs, privacy-preserving distributed data mining, and AI methods for drug discovery and personalized medicine. His work is supported through the Dutch National Research Agenda, the Netherlands Organisation for Scientific Research, Horizon Europe, the European Open Science Cloud, the US National Institutes of Health, and a Marie-Curie Innovative Training Network. He is the editor-in-chief for the journal Data Science and is internationally recognized for his contributions in bioinformatics, biomedical informatics, and semantic technologies including ontologies and linked data.
Richard's entangled aventures in wonderlandRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
Rudolf Happle - Dermatología, University of Freiburg Medical Center, Freiburg, Alemania.
1. Rudolf Happle
Department of Dermatology
University of Freiburg
Germany
A fresh look at capillary malformations:A fresh look at capillary malformations:
Why do we need particular namesWhy do we need particular names
for different vascular skin lesions?for different vascular skin lesions?
Madrid
10 May 2018
8. Lee MS et al: J Am Acad Dermatol 2013
According to the ISSVA,
the diagnosis is capillary malformation
9.
10. Klippel-Trenaunay syndrome: CM + VM +/− LM + limb overgrowth
Parkes-Weber syndrome: CM + AVF + limb overgrowth
Servelle-Martorell syndrome: limb VM + bone undergrowth
Sturge-Weber syndrome: facial + leptomeningeal CM + ocular anomalies +/
− bone and/or soft tissue overgrowth
Limb CM + congenital nonprogressive limb hypertrophy
Maffucci syndrome: VM +/− spindle cell hemangioma + enchondroma
Macrocephaly-CM (M-CM)/megalencephaly-CM-polymicrogyria (MCAP)
Microcephaly-CM (MICCAP)
CLOVES syndrome: LM + VM + CM +/− AVM + lipomatous overgrowth
Proteus syndrome: CM, VM and/or LM + asymmetric somatic overgrowth
Bannayan-Riley-Ruvalcaba syndrome: AVM + VM + macrocephaly,
lipomatous overgrowth
Wassef M et al and ISSVA Board and Scientific Committee: Pediatrics 2015
Vascular Anomalies Classification:
Recommendations From the International Society for the Study of Vascular Anomalies
For clinical dermatologists
this classification is worthless!
18. Diociaiuti A et al:
J Am Acad Dermatol 2005
Jordaan HF, Happle R:
Br J Dermatol 2008
Phacomatosis spilorosea:
Macular nevus spilus combined with nevus roseus
Happle R:
J Eur Acad Dermatol Venereol
2015
19.
20.
21. A rather frequently occurring capillary malformation
that deserves a specific name:
Rhodoid nevus
(Vikkula nevus)
Thanks to
Dr. Regina Fölster-Holst, Kiel, Germany
22. Miikka VikkulaMiikka Vikkula
Professor of Human GeneticsProfessor of Human Genetics
BrusselsBrussels
2003:2003:
A new autosomal dominant phenotypeA new autosomal dominant phenotype
„„capillary malformation-arteriovenous malformation“capillary malformation-arteriovenous malformation“
(CM-AVM), being caused by(CM-AVM), being caused by RASA1RASA1 mutationsmutations
23. 2003:2003:
A new autosomal dominant phenotypeA new autosomal dominant phenotype
„„capillary malformation-arteriovenous malformation“capillary malformation-arteriovenous malformation“
(CM-AVM), being caused by(CM-AVM), being caused by RASA1RASA1 mutationsmutations
24. Revencu N and 51 coauthors:
Hum Mutation 2013
Type 2 segmental manifestation
= bias of ascertainment
25. Revencu N et al: Hum Mutation 2008Revencu N et al: Hum Mutation 2008
„„Capillary malformation-arteriovenous malformation“:Capillary malformation-arteriovenous malformation“:
The arteriovenous malformation is aThe arteriovenous malformation is a
type 2 segmental manifestation of the syndrome!type 2 segmental manifestation of the syndrome!
26. rhodoidesrhodoides = rose-colored= rose-colored
Courtesy ofCourtesy of
Dr. Cornelia Seitz,Dr. Cornelia Seitz,
Göttingen,GermanyGöttingen,Germany
Rhodoid nevusRhodoid nevus
(Vikkula nevus)
27. Courtesy ofCourtesy of
Dr. Cornelia Seitz,Dr. Cornelia Seitz,
Göttingen,GermanyGöttingen,Germany
Why a new name?
28. „„Nomina si nescis, perit et cognitio rerum.“Nomina si nescis, perit et cognitio rerum.“
Carl von LinnéCarl von Linné
1707-17781707-1778
Si no se conocen los nombres, losSi no se conocen los nombres, los
conocimientos de estas cosas se pierden.conocimientos de estas cosas se pierden.
34. Conclusion:Conclusion:
Rhodoid nevi (Vikkula nevi) occur rather frequently.Rhodoid nevi (Vikkula nevi) occur rather frequently.
They are inherited as an autosomal dominant trait.They are inherited as an autosomal dominant trait.
An arteriovenous malformation („CM-AVM“)An arteriovenous malformation („CM-AVM“)
isis notnot an obligatory criterion.an obligatory criterion.
They reflect a mutation inThey reflect a mutation in RASA1 or EPHB4RASA1 or EPHB4..
35.
36. Torrelo A et al:
J Eur Acad Dermatol Venereol 2006
Del Boz González J et al:
An Pediatr (Barc) 2008
Cutis marmorata telangiectatica congenita
37.
38. …is a hallmark of
congenital livedo reticularis-megalencephaly syndrome
(„macrocephaly-capillary malformation syndrome“)
Congenital livedo reticularis
39. Cutis marmorataCutis marmorata
telangiectatica congenitatelangiectatica congenita
CongenitalCongenital
livedo reticularislivedo reticularis
The cause is so far
unknown
PIK3CA
Rivière JB et al:
Nat Genet 2012
41. Swarr DT et al:Swarr DT et al:
Prenatal Diagnosis 2013Prenatal Diagnosis 2013
Congenital livedo reticularis
Gonzalez ME et al:
Pediatr Dermatol 2009
42. Lee MS et al: J Am Acad Dermatol 2013
Congenital
livedo reticularis
43.
44. Plötz SG et al:
Br J Dermatol 1998
Thanks to Dr. Sigrid Tinschert,
Berlin, Germany
Chen WC et al: Dermatology 2006
Thanks to Dr. Henning Hamm,
Würzburg, Germany
Port-wine nevus
of the Proteus type
Port-wine nevus
of the CLOVES type
Angiokeratoma
circumscriptum
Segmental angioma
serpiginosum
Nevus anemicus Nevus vascularis mixtus
Thanks to Dr. Helena de las Heras,
Madrid, Spain
Other capillary nevi
45.
46. Capillary nevi in limbo
(capillary malformations that
probably represent nevi)
49. Macrocephaly–Capillary Malformation: Analysis of 13 Patients and Review of the
Diagnostic Criteria
Víctor Martínez-Glez, Valeria Romanelli, María A. Mori, Ricardo Gracia, Mabel Segovia,
Antonio Gonzalez-Meneses, Juan C. Lopez-Gutierrez, Esther Gean, Loreto Martorell, Pablo Lapunzina
Am J Med Genet Part A 2010
Midfacial port-wine patch
50.
51. Krämer D et al: Int J Dermatol 2016
Midfacial port-wine patch of the CLAPO type
52. Am J Med Genet Part A 2008
PIK3CA
Rodriguez-Laguna L et al: Genet Med 2018
53. Krämer D et al: Int J Dermatol 2016
Midfacial port-wine patch of the CLAPO type
56. Isidor B et al: Am J Med Genet 2011
Carter-Mirzaa macules
„„MICCAP“MICCAP“
STAMPBSTAMPB mutationsmutations
Grimaldi M et al: Acta Derm Venereol 2006
Unilateral punctate telangiectasia
Unilateral nevoid telangiectasia of the patchy type
Other capillary nevi in limbo
73. Ruggieri M et al: Am J Med Genet 2012Ruggieri M et al: Am J Med Genet 2012
Nevus vascularis mixtus syndromeNevus vascularis mixtus syndrome
74. Nevus vascularis mixtus syndromeNevus vascularis mixtus syndrome
Intracerebral vascular malformations
Ruggieri M et al: Am J Med Genet 2012Ruggieri M et al: Am J Med Genet 2012